Free Trial Information
BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...NLRP3 inhibitor that has completed a Phase I trial for cryopyrin-associated periodic syndrome (CAPS); and Somalix...
Read More
BioCentury | Jun 4, 2020
Finance

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

...Phase I testing. Inflazome Ltd. has two programs, Inzomelid for CIAS1-associated periodic syndrome (CAPS) and Somalix...
Read More
Items per page:
1 - 2 of 2